ARYA Sciences Acquisition IV, the fourth healthcare-focused blank check company formed by Perceptive Advisors, filed on Wednesday with the SEC to raise up to $130 million in an initial public offering.
The New York, NY-based company plans to raise $130 million by offering 13 million shares at a price of $10. The offering does not contain any warrants. The company may raise up to an additional $25 million in a forward purchase agreement with its sponsor that will close concurrently with the initial business combination. At the proposed deal size, ARYA Sciences Acquisition IV will command a market value of $167 million.
The company is led by Chairman Joseph Edelman, who serves as Founder and CEO of Perceptive Advisors; CEO and Director Adam Stone, who serves as Chief Investment Officer of Perceptive Advisors; and CFO and Director Michael Altman, who is a Managing Director at Perceptive Advisors. The team's previous SPACs include ARYA Sciences Acquisition III (ARYA; +99% from $10 offer price), which raised $130 million in August 2020 and is pending a combination with Nautilus Biotechnology; ARYA Sciences Acquisition II, which completed its acquisition of Cerevel Therapeutics (CERE; +54%) in October 2020; and ARYA Sciences Acquisition, which completed its acquisition of Immatics Biotechnologies (IMTX; +13%) in July 2020.
ARYA Sciences Acquisition IV intends to target the healthcare industry, with a specific focus on North American or European companies in the life sciences and medical technology sectors where management has extensive investment experience.
The New York, NY-based company was founded in 2020 and plans to list on the Nasdaq under the symbol ARYD. Goldman Sachs and Jefferies are the joint bookrunners on the deal.
